The role of calcium sensitive and vitamin D receptors in the pathogenesis of sporadic multiple parathyroid gland disease

BACKGROUND: Sporadic multiple parathyroid gland disease is ¼ cases of primary hyperparathyroidism (PHPT). However, a single tactic for diagnosing and operating volume in patients with this variant of PHPT has not yet been developed. One of the possible directions in the search for pathogenetically substantiated methods of diagnosis and treatment is the study of the molecular genetic features of the disease and associated clinical and laboratory factors.

AIM: To study the features of the expression of calcium sensitive (CaSR) and vitamin D (VDR) receptors on the surface of parathyroid cells in primary hyperparathyroidism with solitary and multiple lesions of the parathyroid glands, as well as its changes under the influence of a decrease in the filtration function of the kidneys.

MATERIALS AND METHODS: In a single center observational prospective study with retrospective data collection, there were patients who during 2019–2021. operated on for PHPT, secondary hyperparathyroidism (SHPT) and all cases of tertiary hyperparathyroidism (THPT) operated during 2014–2021. The expression of CaSR, VDR and its relationship with the main laboratory parameters, the clinical variant of hyperparathyroidism, and the morphological substrate were studied.

RESULTS: The study included 69 patients: 19 with multiple and 25 with solitary PTG near PHPT, 15 with SHPT, 10 with THPT. A statistically significant decrease in the frequency of detection of normal expression of CaSR and VDR receptors occurs in any morphological variant of hyperparathyroidism and is observed in 93–60% of drugs. A decrease in the normal expression of CaSR in hyperplasia is detected statistically significantly less frequently than in adenoma (p≤0.01). The median expression intensity in adenoma was 2.5 (2:3), in hyperplasia 3.5 (3–4) (p≤0.01). The difference in the molecular mechanisms of the development of hyperparathyroidism with a predominance of a morphological substrate in the form of adenoma (PHPT with solitary adenoma) or hyperplasia (SHPT and PHPT with multiple PTG lesions) is realized in the frequency of maintaining normal CaSR expression in the PTG tissue. These mechanisms are implemented at the local level, their variability does not change under the influence of RRT. A common molecular genetic mechanism for the development of hyperparathyroidism with a predominance of a morphological substrate in the form of adenoma or hyperplasia has been found to reduce the frequency of maintaining normal VDR expression in PTG (up to 7–13%), p<0.01. This mechanism is implemented at the local level, its variability changes under the influence of RRT, reaching statistically significant differences in patients with THPT.

CONCLUSION: The study demonstrates the features of changes in the expression of CaSR and VDR in PHPT with multiple lesions of the parathyroid glands. The relationship between the expression of these receptors and the clinical variant of hyperparathyroidism, the morphological substrate, the main laboratory parameters, and renal function was shown.

1. Dedov II, Melnichenko GA, Mokrysheva NG, et al. Primary hyperparathyroidism: the clinical picture, diagnostics, differential diagnostics, and methods of treatment. Problems of Endocrinology. 2016;62(6):40-77. (In Russ.). doi: https://doi.org/10.14341/probl201662640-77

2. Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356-367. doi: https://doi.org/10.1016/S2213-8587(19)30066-X

3. Barczyński M, Bränström R, Dionigi G, Mihai R. Sporadic multiple parathyroid gland disease — a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbeck’s Arch Surg. 2015;400(8):887-905. doi: https://doi.org/10.1007/s00423-015-1348-1

4. Brown EM, Pollak M, Seidman CE, et al. Calcium-ion-sensing cell-surface receptors. N Engl J Med. 1995;333(4):234-240. doi: https://doi.org/10.1056/NEJM199507273330407

5. Demay MB, Kiernan MS, DeLuca HF, Kronenberg HM. Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci. 1992;89(17):8097-8101. doi: https://doi.org/10.1073/pnas.89.17.8097

6. Latus J, Lehmann R, Roesel M, et al. Involvement of α-klotho, fibroblast growth factor-, vitamin-D — and calcium-sensing receptor in 53 patients with primary hyperparathyroidism. Endocrine. 2013;44(1):255-263. doi: https://doi.org/10.1007/s12020-013-9881-6

7. Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int. 2008;74(3):276-288. doi: https://doi.org/10.1038/sj.ki.5002287

8. Ritter CS, Finch JL, Slatopolsky EA, Brown AJ. Parathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptor. Kidney Int. 2001;60(5):1737-1744. doi: https://doi.org/10.1046/j.1523-1755.2001.00027.x

9. Lopez I, Mendoza FJ, Aguilera-Tejero E, et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int. 2008;73(3):300-307. doi: https://doi.org/10.1038/sj.ki.5002675

10. Walker MD, Bilezikian JP. Vitamin D and primary hyperparathyroidism: more insights into a complex relationship. Endocrine. 2017;55(1):3-5. doi: https://doi.org/10.1007/s12020-016-1169

11. Maganeva IS, Pigarova EA, Shulpekova NV, et al. Vitamin D metabolite and calcium phosphorus metabolism in in patients with primary hyperparathyroidism on the background of bolus therapy with colecalciferol. Problems of Endocrinology. 2021;67(6):68-79. (In Russ.). doi: https://doi.org/10.14341/probl12851

12. Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int. 2008;74(3):276-288. doi: https://doi.org/10.1038/sj.ki.5002287

13. Mokrysheva NG, Eremkina AK, Mirnaya SS, et al. The clinical practice guidelines for primary hyperparathyroidism, short version. Problems of Endocrinology. 2021;67(4):94-124. (In Russ.). doi: https://doi.org/10.14341/probl12801

14. Bikbov BT, Tomilina NA. Renal replacement therapy for ESRD patients in Russian Federation, 1998-2011 Report of Russian RRT Registry. Part 1. Nephrology and dialysis. 2014;16(1):11-127. (In Russ.).

15. Jamal SA, Miller PD. Secondary and Tertiary Hyperparathyroidism. J Clin Densitom. 2013;16(1):64-68. doi: https://doi.org/10.1016/j.jocd.2012.11.012

16. Pitt SC, Sippel RS, Chen H. Secondary and tertiary hyperparathyroidism, state of the art surgical management. Surg Clin North Am. 2009;89(5):1227-1239. doi: https://doi.org/10.1016/j.suc.2009.06.011

17. Sudhaker Rao D, Han ZH, Phillips ER, et al. Reduced vitamin D receptor expression in parathyroid adenomas: implications for pathogenesis. Clin Endocrinol (Oxf). 2000;53(3):373-381. doi: https://doi.org/10.1046/j.1365-2265.2000.01081.x

18. Varshney S, Bhadada SK, Saikia UN, et al. Simultaneous expression analysis of vitamin D receptor, calcium-sensing receptor, cyclin D1, and PTH in symptomatic primary hyperparathyroidism in Asian Indians. Eur J Endocrinol. 2013;169(1):109-116. doi: https://doi.org/10.1530/EJE-13-0085

19. Lee HJ, Seo UH, Kim WY, et al. Calcium-sensing receptor and apoptosis in parathyroid hyperplasia of patients with secondary hyperparathyroidism. J Int Med Res. 2013;41(1):97-105. doi: https://doi.org/10.1177/0300060513476600

20. Singh P, Bhadada SK, Dahiya D, et al. Reduced calcium sensing receptor (casr) expression is epigenetically deregulated in parathyroid adenomas. J Clin Endocrinol Metab. 2020;105(9):3015-3024. doi: https://doi.org/10.1210/clinem/dgaa419

21. Taniguchi M, Tokumoto M, Matsuo D, et al. Persistent hyperparathyroidism in renal allograft recipients: vitamin D receptor, calcium-sensing receptor, and apoptosis. Kidney Int. 2006;70(2):363-370. doi: https://doi.org/10.1038/sj.ki.5001549

22. Rodriguez ME, Almaden Y, Cañadillas S, et al. The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Physiol Physiol. 2007;292(5):F1390-F1395. doi: https://doi.org/10.1152/ajprenal.00262.2006